ホーム>>Signaling Pathways>> Endocrinology and Hormones>> Androgen Receptor>>ORM-15341

ORM-15341

カタログ番号GC32402

ORM-15341 は、完全長 hAR とアンドロゲン応答性ルシフェラーゼ レポーター遺伝子構築物を安定して発現する AR-HEK293 細胞でのトランス活性化アッセイによって示されるように、38 nM の IC50 値を持つヒト AR (hAR) の強力な完全アンタゴニストです。

Products are for research use only. Not for human use. We do not sell to patients.

ORM-15341 化学構造

Cas No.: 1297537-33-7

サイズ 価格 在庫数 個数
10mM (in 1mL DMSO)
$69.00
在庫あり
5mg
$63.00
在庫あり
10mg
$108.00
在庫あり
50mg
$405.00
在庫あり
100mg
$378.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

ORM-15341 is a potent and full antagonist for human AR (hAR) with IC50 values of 38 nM as shown by transactivation assays in AR-HEK293 cells stably expressing full-length hAR and an androgen-responsive luciferase reporter gene construct.IC50 value: 38 nMTarget: androgen receptorin vitro: In competitive AR binding assays, the inhibition constant (Ki) values of ORM-15341 was 8 nM. ORM-15341 functions as a full antagonist for all tested mutant ARs , with IC50 of 25, 51, 700, and 1160 nM for wtAR, AR(F876L), AR(T877A), and AR(W741L).

[1]. Moilanen AM, et al. Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms toandrogen signaling-directed prostate cancer therapies. Sci Rep. 2015 Jul 3;5:12007. doi: 10.1038/srep12007. [2]. Toermaekangas Olli, et al. Preparation of heteroaryl carboxamides as androgen receptor modulators. From PCT Int. Appl. (2012), WO 2012143599 A1 20121026.

レビュー

Review for ORM-15341

Average Rating: 5 ★★★★★ (Based on Reviews and 8 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for ORM-15341

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.